Systematic review on quinolone-phage synergy mechanisms and clinical strategies

Photo by Giovanni Crisalfi / Unsplash

Frontiers in Medicine Published May 20, 2026 Medically reviewed May 20, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider the proposed PAS framework for quinolones, but recognize evidence certainty depends on underlying study quality.

This is a systematic review of mechanisms and strategies for phage-antibiotic synergy (PAS) with quinolone antibiotics and bacteriophages. The review synthesizes evidence on synergistic effects, which manifest across multiple dimensions: bacterial morphological remodeling, activation of temperate phages, disruption of biofilm barriers, potentiation of functional proteins, dual regulation of resistance evolution, and synergy with the host immune system. It also identifies antagonistic effects, primarily triggered by high-concentration antibiotics interfering with phage proliferation, adaptive phenotypic alterations of bacteria, and imbalanced administration strategies.

The authors do not report pooled effect sizes, p-values, confidence intervals, or absolute numbers, as this is a qualitative synthesis of mechanisms. The review provides a framework to guide the standardized clinical application of quinolone-based PAS, including sequential administration, sub-inhibitory antibiotic concentrations paired with minimum effective MOI of phages, rational selection of phages, and individual regimen tailoring.

Key limitations noted are that the evidence is synthesized from reviewed studies, and certainty depends on the quality of the underlying primary studies, which is not assessed in this abstract. The review does not establish causation from primary trials. Practice relevance is restrained to a conceptual framework, as specific clinical efficacy or safety outcomes cannot be inferred from this synthesis.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

The escalating global crisis of bacterial antimicrobial resistance (AMR) has significantly limited the clinical efficacy of quinolone antibiotics, while the use of phages alone suffers from inherent limitations, including a narrow host spectrum and the propensity to rapidly induce phage resistance. Consequently, combined antimicrobial therapy, defined as phage-antibiotic synergy (PAS), has emerged as a pivotal direction to address the challenges. The specific objectives of this review are to systematically dissect the bidirectional synergistic and antagonistic interactions between quinolone antibiotics and bacteriophages, define the key regulatory factors governing their combined effects, and establish an evidence-based framework to guide the standardized clinical application of quinolone-based PAS. This paper systematically reviews the mechanisms underlying the synergistic and antagonistic interactions between quinolone antibiotics and bacteriophages. The synergistic effects are manifested across multiple dimensions: bacterial morphological remodeling, activation of temperate phages, disruption of biofilm barriers, potentiation of functional proteins, dual regulation of resistance evolution, and synergy with the host immune system. In contrast, antagonistic effects are primarily triggered by high-concentration antibiotics interfering with phage proliferation, adaptive phenotypic alterations of bacteria, and imbalanced administration strategies. Simultaneously, we summarize standardized clinical optimization strategies, including sequential administration, sub-inhibitory antibiotic concentrations paired with the minimum effective multiplicity of infection (MOI) of phages, rational selection of broad-host-range and highly lytic phages, and individual regimen tailoring to match the specific infectious scenario and host immune status. We further analyze key challenges in the clinical translation of this therapeutic approach and propose future research directions, offering a framework to guide both mechanistic studies and clinical implementation of PAS as a strategy to mitigate antimicrobial resistance.